摘要
目的:探讨通心络胶囊对不稳定型心绞痛患者经皮冠状动脉介入治疗(PCI)过程中的保护作用及可能的机制。方法:选择不稳定型心绞痛患者110例,随机分为通心络胶囊组(57例)和常规治疗组(53例),通心络胶囊组术前给予通心络胶囊治疗7d,术后继续服药0.5年;常规治疗组给予常规药物治疗。两组患者均在PCI术前、术后24h、术后1个月、术后6个月采肘静脉血,检测hs-CRP、IL-6mRNA、内皮素(ET)和内皮依赖性血管舒张功能(FMD)。6个月后再次行CAG检查,了解再狭窄情况及再次冠脉事件的发生率。结果:术后6个月IL-6mRNA表达、hs-CRP、ET较术前降低,通心络胶囊组较常规治疗组显著下降(P<0.01)。hs-CRP的变化与IL-6mRNA表达的变化一致。术后6个月,两组FMD均明显升高,通心络胶囊组升高更明显(P<0.01)。随访期间,通心络胶囊组心绞痛发生率、再次PCI、累计主要不良心脏事件及再狭窄率均较常规治疗组明显降低(P<0.05或P<0.01)。结论:通心络胶囊可明显抑制PCI术后炎症反应,保护、改善内皮功能,从而减少随访期间心绞痛发生率、再次PCI、累计主要不良心脏事件及再狭窄率的发生。
Objective:To investigate the protective effects of Tongxinluo Capsules on interventional therapy of patients with unstable angina.Methods:110 patients with unstable angina were randomly divided into experimental conventional therapy group(53 cases,treated with conventional therapy) and Tongxinluo Capsules group(57 cases,treated with Tongxin luo Capsules for 7 days before operation and continued to administer Tongxinluo Capsules for 0.5 years).The two groups were collected venous blood at the time of preoperative,24 h after operation,one month after operation,six months after operation.All the patients were determined hs-CRP,IL-6 mRNA,FMD and ET.Six months later,the message of resteno sis and heart incidents were collected.Results:After six months' therapy,Tongxinluo Capsules group obviously reduced with the IL-6 mRNA expression,hs-CRP and ET level(P0.01),and oviously advanced with FMD(P0.01).The angina incidence rate,PCI again and unhealthy conscience incident were lower(P0.05 or P0.01).Conclusion:The treatment of Tongxinluo Capsules can refrain inflammatory reaction,protect endodermis function,and reduce unhealthy conscience inci dence.
出处
《中国医药导报》
CAS
2010年第20期17-20,共4页
China Medical Herald